Shield Therapeutics plc (LON:STX – Get Free Report)’s stock price traded up 22.8% during trading on Wednesday . The stock traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.50 ($0.04). 5,293,617 shares changed hands during mid-day trading, an increase of 126% from the average session volume of 2,340,523 shares. The stock had previously closed at GBX 2.85 ($0.04).
Shield Therapeutics Stock Performance
The company has a 50 day moving average of GBX 2.70 and a 200 day moving average of GBX 3.31. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The firm has a market cap of £26.77 million, a price-to-earnings ratio of -85.58 and a beta of 1.42.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Read More
- Five stocks we like better than Shield Therapeutics
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- How to Invest in Biotech Stocks
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
